Stock listing
Hanover:1VT Viking Therapeutics, Inc. Aktie
German listing (Hanover) of Viking Therapeutics, Inc. · home listing NASDAQ:VKTX
Follow Viking Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:VKTX
$25.17 USD -2.20 (-8.0%)
Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:VKTX
- Ticker
- Hanover:1VT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Hanover
- Currency
- EUR
What changed lately
Latest news release · Oct 14, 2026
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
Latest earnings call · Jul 29, 2026
Viking Therapeutics (NASDAQ:VKTX) Q2 2026 Earnings Call
Replay and transcript
Latest deck · September 2026
Technical Presentation (September 2026)
Technical · 14 slides
Calls
Replays
Viking Therapeutics (NASDAQ:VKTX) Q2 2026 Earnings Call
Wed, Jul 29, 2026 · 4:30 PM ET
Watch TranscriptViking Therapeutics (NASDAQ:VKTX) Q1 2026 Earnings Call
Wed, Apr 29, 2026 · 4:30 PM ET
Watch TranscriptViking Therapeutics (NASDAQ:VKTX) Q4 2025 Earnings Call
Wed, Feb 11, 2026 · 4:30 PM ET
Watch Transcript
Latest news
Financings
Public offering of common stock
Sep 28, 2026
Closed: US$200M raised · US$35 a share · Morgan Stanley & Co. LLC +12
Dealers: Morgan Stanley & Co. LLC (co-lead), J.P. Morgan Securities LLC (co-lead), J.P. Morgan (co-lead), Jefferies (co-lead), Leerink Partners (co-lead), William Blair (co-lead), Raymond James (co-lead), Oppenheimer & Co., Canaccord Genuity, H.C. Wainwright & Co., B. Riley Securities, Maxim Group LLC, Laidlaw & Company (U.K.) Ltd.
Use of proceeds: Clinical development and commercialization of VK2735, development of VK3019, other R&D, working capital and general corporate purposes
2.00% convertible senior notes due 2032
Sep 28, 2026
Closed: US$258.75M raised · Morgan Stanley & Co. LLC +5
Dealers: Morgan Stanley & Co. LLC (co-lead), J.P. Morgan Securities LLC (co-lead), J.P. Morgan (co-lead), Jefferies (co-lead), Leerink Partners (co-lead), William Blair (co-lead)
Use of proceeds: Clinical development and commercialization of VK2735, development of VK3019, other R&D, working capital and general corporate purposes
Decks
Technical Presentation (September 2026)
Technical · 14 slides · September 2026
Investor Presentation (August 2026)
Investor deck · 35 slides · August 2026
Biotech Showcase 2016
Conference · 28 slides · Jan 11, 2016
Viking Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 146 in all · newest Oct 14, 2026 · oldest 2019
- Calls
- 18 calls with a replay · 18 with a transcript · latest Jul 29, 2026
- Decks
- 3 decks · latest September 2026
Where Viking Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:VKTX · Home listing | NASDAQ | United States | USD |
| gettex:1VT | gettex | Germany | EUR |
| LS Exchange:A12GD6 | LS Exchange | Germany | EUR |
| Tradegate:1VT | Tradegate | Germany | EUR |
| Frankfurt:1VT | Frankfurt | Germany | EUR |
| BX Swiss:VKTX | BX Swiss | Switzerland | CHF |
| Lang & Schwarz:A12GD6 | Lang & Schwarz | Germany | EUR |
| Milan:1VKTX | Milan | Italy | EUR |
| LSE:0VQA | LSE | United Kingdom | USD |
| BOATS:VKTX | BOATS | United States | USD |
| Stuttgart:1VT | Stuttgart | Germany | EUR |
| Dusseldorf:1VT | Dusseldorf | Germany | EUR |
| Hamburg:1VT | Hamburg | Germany | EUR |
| Munich:1VT | Munich | Germany | EUR |
| Hanover:1VT · This page | Hanover | Germany | EUR |
| Xetra:1VT | Xetra | Germany | EUR |
Log in to ask 6ix AI your own questions about Viking Therapeutics, Inc.